A5019149870- CAR-T cell therapy research
- Academic Publishing and Open Access
- Meta-analysis and systematic reviews
- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- scientometrics and bibliometrics research
- Atherosclerosis and Cardiovascular Diseases
- Cancer-related Molecular Pathways
- Biosimilars and Bioanalytical Methods
- Virus-based gene therapy research
- COVID-19 diagnosis using AI
- Animal testing and alternatives
- Silicon Carbide Semiconductor Technologies
- Biomedical Ethics and Regulation
- PARP inhibition in cancer therapy
- Advanced Breast Cancer Therapies
- Immunotherapy and Immune Responses
Instituto Nacional do Câncer
2020-2025
Ludwig Cancer Research
2024
University of Lausanne
2024
Universidade Federal do Rio de Janeiro
2018-2020
Preprint usage is growing rapidly in the life sciences; however, questions remain on relative quality of preprints when compared to published articles. An objective dimension that readily measurable completeness reporting, as transparency can improve reader's ability independently interpret data and reproduce findings.
Abstract Chimeric antigen receptor (CAR) T cell therapy is increasingly being adopted as a clinical modality for patients with relapsed/refractory hematological malignancies. Despite the efficacy of CAR-T therapy, considerable fraction still relapses during first months following infusion. The limited efficiency thought to relate epigenetic mechanisms involved in suppression and dysfunction. Here, screening multiple inhibitors revealed that targeting PRC2 consistently induced development...
Abstract Background Preprint usage is growing rapidly in the life sciences; however, questions remain on relative quality of preprints when compared to published articles. An objective dimension that readily measurable completeness reporting, as transparency can improve reader’s ability independently interpret data and reproduce findings. Methods In this observational study, we initially independent samples articles bioRxiv PubMed-indexed journals 2016 using a reporting questionnaire. After...
Throughout the global coronavirus pandemic, we have seen an unprecedented volume of COVID-19 researchpublications. This vast body evidence continues to grow, making it difficult for research users keep up with pace evolving findings. To enable synthesis this timely use by researchers, policymakers, and other stakeholders, developed automated workflow collect, categorise, visualise from primary studies. We trained a crowd volunteer reviewers annotate studies relevance COVID-19, study...
Anti-CD19 CAR-T cell therapy represents a breakthrough in the treatment of B-cell malignancies, and it is expected that this modality will soon cover range solid tumors as well. Therefore, universal cheap sensitive method to detect CAR expression foremost importance. One possibility use epitope tags such c-Myc, HA or FLAG attached extracellular domain, however, necessary determine whether these can influence binding with its target molecule. Here, we conducted in-silico structural modelling...
The ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines are reportingguidelines designed to improve transparency and facilitate critical assessment ofexperiments involving animal research. Although it represents essential reportinginformation for experiments, compliance with items is not commonlydemanded by journals often lacking in studies. this small pilot project, weevaluated 2.0 10 64 papers from 2018 2020,either citing or the manuscripts. Papers that cited hadslightly...